Navigation Links
Results triple researchers' projections with use of adult stem cells for heart failure
Date:11/14/2011

ORLANDO, Fla. Patients suffering from heart failure due to a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that involved infusing them with their own stem cells. The results triple the 4 percent improvement average the researchers projected for the Phase I trial.

Results of the trial are published today (Nov. 14) in The Lancet and concurrently presented at the American Heart Association Scientific Sessions in Orlando, Fla. They are the first report of administering subjects' own cardiac stem cells in humans; previous studies have used stem cells harvested from bone marrow.

The research team, led by Dr. Roberto Bolli of the University of Louisville and Dr. Piero Anversa at Brigham and Women's Hospital/Harvard Medical School in Boston, conducted the trial, called "SCIPIO" an acronym for "Cardiac Stem Cells in Patients with Ischemic CardiOmyopathy."

The 16 SCIPIO patients were diagnosed with heart failure following a myocardial infarction and had a left ventricular ejection fraction (LVEF) of 40 percent or lower. LVEF is a standard measure of the heart's pumping capability; it measures how much blood is ejected from the left ventricle during a heartbeat. The normal LVEF is 50 percent or higher.

The investigators harvested cardiac stem cells, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from the patients during coronary artery bypass surgery conducted at Jewish Hospital in Louisville. The stem cells were purified in Anversa's lab in Boston and allowed to grow. Once an adequate number of stem cells were produced about one million Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the infarction.

In designing the trial, Bolli and Anversa examined data from previous studies of bone marrow-derived stem cells and projected an average improvement in LVEF of 4-5 percent for all patients. They witnessed an 8.5 percent improvement just four months following the reintroduction of stem cells and 12 percent after one year.

The researchers also conducted MRI studies on the patients' hearts and saw that the size of the scarred regions had decreased a result that seemingly begins to disprove the long-held belief that once scarring occurs, the heart tissue is forever dead.

Bolli who is lead author of The Lancet article and presenter of the data at the Scientific Sessions says that the adult stem cell protocol could become one of the greatest advancements in cardiac treatment in a generation.

"The results are striking," Bolli said. "While we do not yet know why the improvement occurs, we have no doubt now that ejection fraction increased and scarring decreased. If these results hold up in future studies, I believe this could be the biggest revolution in cardiovascular medicine in my lifetime."

His colleague Anversa has been studying cardiac stem cells' potential to regenerate myocardial cells damaged from heart failure since the 1990s. "Seeing these cells given successfully to very sick patients is the most rewarding experience that a physician-scientist can have in his or her lifetime," said Anversa, noting that the work was a major team effort that involved several senior members in both his and Bolli's laboratories.

The SCIPIO trial was funded by a grant from the National Heart, Lung and Blood Institute. The researchers reiterated that these findings are preliminary and larger-scale studies must be undertaken before the therapy can be widely used.

Bolli already is looking forward to a larger study, he said. "We plan to apply for funding to conduct a Phase II multi-center trial," he said.


'/>"/>

Contact: Jill Scoggins
jill.scoggins@louisville.edu
502-475-2428
University of Louisville
Source:Eurekalert  

Related biology news :

1. Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
2. Reprogramming stem cells to a more basic form results in more effective transplant, study shows
3. Progeria: Promising results from new gene therapy on animals
4. Aware, Inc. Reports Third Quarter 2011 Financial Results
5. Vanderbilt ethicist to study return of results issue involving children in genomics studies
6. CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011
7. Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
8. Aware, Inc. Reports Second Quarter 2011 Financial Results
9. Montana State University team surprised by results of lung, mold study
10. National asthma genetics consortium releases first results
11. Aware, Inc. Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Results triple researchers' projections with use of adult stem cells for heart failure
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric ... ... DERMALOGs Face Matching enables to match face pictures ... the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
(Date:3/22/2017)... March 22, 2017 /PRNewswire/ - FACIT announced a ... or "Propellon"), a start-up created by FACIT focused ... FACIT,s investment, combined with non-dilutive capital, achieves a ... seed funding enables Propellon to accelerate the nomination ... for financing and/or entering a strategic partnership for ...
(Date:3/22/2017)... , March 22, 2017   ... independent provider of product and service solutions ... that it has acquired EPL Archives, Inc., ... customers across the entire regulated product research, ... sample, document storage and ancillary services. EPL ...
(Date:3/22/2017)... Freeport, Grand Bahama (PRWEB) , ... March 21, 2017 , ... ... a free educational seminar as part of their live events series, “Stem Cell Therapy: ... adult stem cell facility under the 2013 Stem Cell Research and Therapy Act, ...
Breaking Biology Technology: